Synmosa Biopharma : 2022 Shareholders' Meeting approved the “lifting of non-competition restrictions on newly appointed directors and their representatives”case.
Synmosa's 2022 Shareholders' Meeting approved the
"lifting of non-competition restrictions on newly
appointed directors and their representatives"case.
Date of events
2022/05/25
To which item it meets
paragraph 21
Statement
1.Date of the shareholders' meeting resolution:2022/05/25
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
Director-Lin, Chih-Hui
Director-Chiu Hui-Lan
Corporate Director-Representative of FORMOSA TIME PHARMACEUTICAL CO., LTD.:
Zhang, You-Peng
Corporate Director-Representative of FORMOSA TIME PHARMACEUTICAL CO., LTD.:
Huang, Li-Wen
Independent Director-Liu, Xiang-Lang
Independent Director-Lin, Xiu-Mei
Independent Director-Wang Chien-Jen
3.Items of competitive conduct in which the officer is
permitted to engage:
The directors of the company have invested in or operated other companies
with the same business scope as the company
4.Period of permission to engage in the competitive conduct:
Term of office as a director (including independent director) of the
company
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
Approved by the chairman after consultation with all shareholders present
and after voting
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter "N/A" below):N/A
7.Company name of the mainland China enterprise and the
officer's position in the enterprise:N/A
8.Address of the mainland China enterprise:N/A
9.Operations of the mainland China enterprise:N/A
10.Impact on the company's finance and business:N/A
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:N/A
12.Any other matters that need to be specified:NONE
Attachments
Original Link
Original Document
Permalink
Disclaimer
Synmosa Biopharma Corporation published this content on 25 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2022 16:11:30 UTC.
SYNMOSA BIOPHARMA CORPORATION is a Taiwan-based company principally engaged in the manufacture and sales of various kinds of pharmaceuticals and medical equipment. The Company's main products include respiratory drugs, cardiovascular and urinary drugs, gastrointestinal drugs, hormones, anti-tumor drugs, antibiotics and health products. The Company is also involved in the manufacture and sales of various kinds of cosmetics and animal medicines, as well as various kinds of chemical food additives and beverages. The Company distributes its products in domestic market and to overseas markets.
Synmosa Biopharma : 2022 Shareholders' Meeting approved the “lifting of non-competition restrictions on newly appointed directors and their representatives”case.
SYNMOSA BIOPHARMA CORPORATION 